Tafamidis for Cardiac Transthyretin Amyloidosis
Open Access
- 1 January 2021
- journal article
- research article
- Published by Korean Society of Cardiovascular Disease Prevention in Cardiovascular Prevention and Pharmacotherapy
- Vol. 3 (1) , 1-9
Abstract
Kim D, et al. Cardiovasc Prev Pharmacother. 2021 Jan;3(1):1-9. https://doi.org/10.36011/cpp.2021.3.e1Keywords
This publication has 24 references indexed in Scilit:
- Tafamidis for the treatment of transthyretin-associated familial amyloid polyneuropathyExpert Opinion on Orphan Drugs, 2013
- Safety and Efficacy of RNAi Therapy for Transthyretin AmyloidosisNew England Journal of Medicine, 2013
- Age-Related Oxidative Modifications of Transthyretin Modulate Its AmyloidogenicityBiochemistry, 2013
- Guideline of transthyretin-related hereditary amyloidosis for cliniciansOrphanet Journal of Rare Diseases, 2013
- Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspectiveEuropean Heart Journal, 2012
- Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascadeProceedings of the National Academy of Sciences, 2012
- Aboard transthyretin: From transport to cleavageIUBMB Life, 2010
- Epidemiology of familial amyloid polyneuropathy in Japan: Identification of a novel endemic focusJournal of the Neurological Sciences, 2008
- Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesisAmyloid, 2006
- Molecular Mechanisms of AmyloidosisNew England Journal of Medicine, 2003